Global Consensus Position Statement on the Use of Testosterone Therapy for Women

Susan R. Davis; Rodney Baber; Nicholas Panay; Johannes Bitzer; Sonia Cerdas Perez; Rakibul M. Islam; Andrew M. Kaunitz; Sheryl A. Kingsberg; Irene Lambrinoudaki; James Liu; Sharon J. Parish; JoAnn Pinkerton; Janice Rymer; James A. Simon; Linda Vignozzi; Margaret E. Wierman


J Clin Endocrinol Metab. 2019;104(10):4660-4666. 

In This Article

Abstract and Introduction


This Position Statement has been endorsed by the International Menopause Society, The Endocrine Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, The International Society for the Study of Women's Sexual Health, The North American Menopause Society, The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia, The Royal College of Obstetricians and Gynaecologists, The International Society of Endocrinology, The Endocrine Society of Australia, and The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.*


There are no clearly established indications for testosterone therapy for women. Nonetheless, clinicians have treated women with testosterone for decades, with the intention of alleviating a variety of symptoms, with uncertain benefits and risks. In most countries, testosterone therapy is prescribed off-label such that women are using either testosterone formulations approved for men with dose modification, or compounded therapies. Because of these issues, there is a compelling case for a global consensus Position Statement on testosterone therapy for women based on the available evidence from placebo/comparator randomised controlled trials (RCTs).

This Position Statement was developed, by consensus between the participating organisations, to inform health care professionals of the known benefits and potential risks of testosterone therapy for women. The aims were to provide clear guidance as to which women might benefit from testosterone therapy, identify symptoms, signs, and conditions for which evidence does not support the prescribing of testosterone, explore areas of uncertainty, and to identify any prescribing practices that have the potential to cause harm.

*This Statement is being simultaneously published in the journals Climacteric, Maturitas, Journal of Sexual Medicine, and Journal of Clinical Endocrinology and Metabolism on behalf of the International Menopause Society, The European Menopause and Andropause Society, The International Society for Sexual Medicine, and The Endocrine Society, respectively.